REG - Trellus Health PLC - Directorate Change

Trellus HealthAnnouncement

23/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220623:nRSW8800Pa&default-theme=true

RNS Number : 8800P  Trellus Health PLC  23 June 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Trellus strengthens Board with appointment of Traci Entel as Non-Executive
Director

and

Grant of Options

 

LONDON, U.K. AND NEW YORK, U.S. (23 June 2022). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces the
appointment of Traci Entel as a Non-Executive Director, with immediate effect.

 

Traci has 22 years' experience in healthcare, technology, and financial
services across high-growth and large organisations as a management consultant
and global HR executive. She has been a member of multiple HR leadership teams
and business operating committees and has significant expertise in leading
teams and advising executives on HR strategies, culture, organisational
effectiveness, diversity and inclusion policies, and implementing talent
strategies.

 

Traci is currently a partner at Incandescent, a New York-based management
consultancy firm, where she is focused on partnering with leaders to achieve
their organization, culture, and talent objectives.

 

Previously, as the Head of Employee Experience at Stripe and Head of Talent
Management at BlackRock, Traci led the firms' talent and culture strategies,
including annual performance processes and career development, leadership
development and succession, broader learning, people analytics, inclusion
& diversity, and M&A. At BlackRock, she was also the lead HR Business
Partner for the firm's non-investment functions including technology,
operations, institutional sales, and corporate functions. As Chief Human
Capital Officer at Booz & Company, Traci developed and delivered a
business-back talent strategy and led the integration with PwC to create
Strategy&.

 

Prior to Traci's 10 years in HR leadership roles, she worked in consulting for
14 years partnering with executives in healthcare, consumer products, and
financial services. Starting her career at Mitchell Madison Group, she then
spent 10 years with Katzenbach Partners, which was acquired by Booz &
Company. At Booz & Company, Traci was a Partner in the firm's
Organization, Change and Leadership, and Healthcare practices where she
focused on culture evolution & behavior change, talent strategy, and
frontline effectiveness. She later led the people and cultural integration of
Booz & Company with PwC to form Strategy&.

 

Traci is a Partnership for New York City David Rockefeller Fellow and member
of the Women's Forum of New York.

 

Monique Fayad, CEO of Trellus Health, said: "We are delighted to welcome Traci
Entel to the Trellus Health Board. She brings significant experience in the
creation and implementation of successful HR strategies across a number of
organisations of varying size and in different fields. Her experience in
organisational design, culture and talent management will be invaluable as we
seek to attract and retain the best talent to support the rapid growth of the
business, especially amidst a highly competitive hiring environment."

 

 

Traci Allison Entel (aged 46) does not currently hold any directorships or
partnerships and has not previously held any directorships or partnerships in
the past five years.

 

The Company announces that Traci Entel has been granted options to subscribe
for up to 100,000 ordinary shares of 0.06 pence each in the capital of the
Company (the "Options"), at an exercise price of 40 pence per ordinary share,
as part of her compensation. The Options are exercisable three years from the
date of grant.

 

Traci Entel has no other holdings of ordinary shares or options in the
Company.

 

 

Following this grant, the Company has 4,411,250 options in issue, representing
2.7 per cent of the Company's issued share capital.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the appointment, pursuant to Rule 17 and Schedule 2 paragraph (g)
of the AIM Rules for companies.

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Monique Fayad, CEO                                       Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Louis Ashe-Jepson                         Mob: 07980 541 893 / 07747 515 393

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first digital health company focused on the
intersection of chronic physical conditions and mental health. Trellus
Health integrates its proprietary resilience-based methodology with the
technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden and promoting individual
health behaviors that enable thriving in the face of a chronic condition.
Through its TrellusElevate™ connected care platform and companion App, the
company addresses both clinical and behavioral health together, in context, to
improve outcomes and reduce healthcare costs for patients, employers, and the
healthcare system.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and demand
across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. IBD patients treated using the methodology also
experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following program completion (source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) ).

 

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky,
MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT™ resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Traci Entel
 2    Reason for the notification
 a)   Position/status                                              Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Trellus Health plc
 b)   LEI                                                          2138002FHWJSR8YKP295
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options over ordinary shares of 0.06p each in Trellus Health plc

      Identification code

                                                                   ISIN for Trellus Health plc ordinary shares GB00BNNFM402
 b)   Nature of the transaction                                    Grant of options over ordinary shares

 c)   Price(s) and volume(s)                                        Price(s)   Volume(s)
                                                                   40 pence    100,000
 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price
 e)   Date of the transaction                                      22 June 2022
 f)   Place of the transaction                                     Outside a trading venue

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

22 June 2022

f)

Place of the transaction

Outside a trading venue

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADBGDLRDDDGDD